BRCA1 and neoplasm: We performed all analyses separately for the ER-negative and ER-positive patient groups (Table 1), corresponding to the specific PREDICT models for ER-negative and ER-positive breast cancer and the characteristic tumor phenotypes of the BRCA1 and BRCA2 variant carriers, respectively.